NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis.
B-Lymphocytes
/ cytology
Biomarkers, Tumor
/ metabolism
Brain Neoplasms
/ immunology
Databases, Factual
Disease-Free Survival
Glioma
/ immunology
Humans
Kaplan-Meier Estimate
NF-E2-Related Factor 2
/ genetics
Neoplasm Grading
Neutrophils
/ cytology
Pancreatic Neoplasms
/ immunology
Prognosis
RNA, Messenger
/ metabolism
T-Lymphocytes
/ cytology
Journal
Oxidative medicine and cellular longevity
ISSN: 1942-0994
Titre abrégé: Oxid Med Cell Longev
Pays: United States
ID NLM: 101479826
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
06
2020
revised:
17
08
2020
accepted:
20
09
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
14
5
2021
Statut:
epublish
Résumé
Nuclear factor, erythroid 2 like 2 (NFE2L2, NRF2) is a transcription factor that regulates various antioxidant enzymes. It plays a vital physiological role in regulating oxidative stress and inflammatory response. However, the roles of NFE2L2 in human cancers are still unclear. Our study is aimed at analyzing the prognostic value of NFE2L2 in pan-cancer and at revealing the relationship between NFE2L2 expression and tumor immunity. The present study revealed that NFE2L2 was abnormally expressed and significantly correlated with mismatch repair (MMR) gene mutation levels and DNA methyltransferase expression in human pan-cancer. In particular, pan-cancer survival analysis indicated that NFE2L2 expression was associated with adverse outcomes-overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI)-in adrenocortical carcinoma (ACC), brain lower grade glioma (LGG), and pancreatic adenocarcinoma (PAAD) patients. A positive relationship was also found between NFE2L2 expression and immune infiltration, including B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells, especially in breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), LGG, liver hepatocellular carcinoma (LIHC), and prostate adenocarcinoma (PRAD). Additionally, NFE2L2 expression was positively correlated with the immune score and the expression of immune checkpoint markers in LGG. In conclusion, these results indicate that transcription factor NFE2L2 is a potential prognostic biomarker and is correlated with immune infiltration in LGG.
Identifiants
pubmed: 33101586
doi: 10.1155/2020/3580719
pmc: PMC7569466
doi:
Substances chimiques
Biomarkers, Tumor
0
NF-E2-Related Factor 2
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3580719Informations de copyright
Copyright © 2020 Qiang Ju et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts.
Références
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Carcinogenesis. 2010 Jan;31(1):90-9
pubmed: 19793802
Clin Epigenetics. 2019 Nov 4;11(1):156
pubmed: 31685013
Adv Exp Med Biol. 2020;1224:117-140
pubmed: 32036608
J Invest Dermatol. 2020 Dec;140(12):2442-2454.e5
pubmed: 32360600
Cell Syst. 2018 Mar 28;6(3):282-300.e2
pubmed: 29596783
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nat Rev Drug Discov. 2018 Jul;17(7):468
pubmed: 29904193
Biomed Res Int. 2017;2017:4180703
pubmed: 28261610
Front Pharmacol. 2020 Apr 07;11:441
pubmed: 32317979
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Oxid Med Cell Longev. 2016;2016:1958174
pubmed: 26697129
Gastrointest Cancer Res. 2012 Jan;5(1):19-27
pubmed: 22574233
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Pharmacol Rep. 2017 Jun;69(3):393-402
pubmed: 28267640
Mol Biol Rep. 2020 Mar;47(3):2265-2277
pubmed: 31925644
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Sci Rep. 2017 Oct 26;7(1):14130
pubmed: 29074861
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Mol Cell. 2018 Jul 19;71(2):201-215.e7
pubmed: 30029001
Mol Oncol. 2020 Jun;14(6):1252-1267
pubmed: 32243066
PLoS One. 2015 Aug 06;10(8):e0133876
pubmed: 26247201
Cancer Biol Ther. 2018 Apr 3;19(4):296-305
pubmed: 29313457
Ann N Y Acad Sci. 2018 Dec;1434(1):164-172
pubmed: 29752726
Gut. 2019 Sep;68(9):1653-1666
pubmed: 30902885
Trends Immunol. 2016 Jan;37(1):41-52
pubmed: 26700397
Clin Immunol. 2020 Jul;216:108430
pubmed: 32325251
Front Oncol. 2020 Apr 15;10:424
pubmed: 32351880
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Molecules. 2018 Jul 20;23(7):
pubmed: 30037040
J Exp Clin Cancer Res. 2012 Aug 19;31:66
pubmed: 22901367
Cancer Immun. 2007 Feb 21;7:4
pubmed: 17311363
Nature. 2020 Feb;578(7793):129-136
pubmed: 32025019
Cancer Res. 2008 Oct 1;68(19):7975-84
pubmed: 18829555
Nat Genet. 2020 Mar;52(3):306-319
pubmed: 32024998
Trends Cancer. 2020 May;6(5):380-391
pubmed: 32348734
Arch Biochem Biophys. 2017 Dec 1;635:66-73
pubmed: 29051069
Histol Histopathol. 2018 Aug;33(8):791-801
pubmed: 29441509
Nat Commun. 2019 Aug 8;10(1):3578
pubmed: 31395880
Eur J Cancer. 2018 Sep;101:191-200
pubmed: 30077124
J Cell Physiol. 2020 Apr;235(4):3119-3130
pubmed: 31549397
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Int J Cancer. 2016 Sep 1;139(5):1129-39
pubmed: 27074317
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Gut. 2017 Jan;66(1):157-167
pubmed: 26452628
Am J Pathol. 2011 Sep;179(3):1455-70
pubmed: 21741942
Nat Commun. 2020 Apr 24;11(1):1980
pubmed: 32332764
Oxid Med Cell Longev. 2019 Jan 8;2019:7090534
pubmed: 30728889
J Infect Dis. 2020 Feb 18;221(5):830-840
pubmed: 31586389
Bioengineered. 2020 Dec;11(1):661-678
pubmed: 32434423
Nature. 2020 Feb;578(7793):102-111
pubmed: 32025015
J Pathol. 2020 Apr;250(5):518-531
pubmed: 32141610
Oncotarget. 2020 Apr 07;11(14):1244-1256
pubmed: 32292574
Cancer Cell. 2012 Jul 10;22(1):66-79
pubmed: 22789539
Semin Oncol. 2015 Aug;42(4):523-38
pubmed: 26320058
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Int J Oncol. 2020 May;56(5):1284-1293
pubmed: 32319586
Ther Adv Respir Dis. 2016 Oct;10(5):444-54
pubmed: 27480166
Cancer Microenviron. 2013 Aug;6(2):123-33
pubmed: 23242673
Oxid Med Cell Longev. 2019 Sep 4;2019:2647068
pubmed: 31687076
Orv Hetil. 2018 Jan;159(1):3-15
pubmed: 29291647